论文部分内容阅读
First-generation epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs),including gefitinib and erlotinib,have proven to be highly effective agents for advanced non-small cell lung cancer(NSCLC)in patients harboring an activating EGFR muta